Have a personal or library account? Click to login
CEACAM1 - A Promising Biomarker for Melanoma Cover

CEACAM1 - A Promising Biomarker for Melanoma

Open Access
|Jan 2022

Abstract

Malignant melanoma is the third most common skin cancer, but it also remains the most aggressive. Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a promising diagnostic and prognostic biomarker for melanoma, because its expression is important for tumour development. This review aims at highlighting the most recent discoveries regarding CEACAM1 and its correlation to the diagnosis and prognosis of malignant melanoma. National Library of Medicine (NIH) PubMed was used for selecting articles published between 2004-2021, based on their relevance and novelty. With its multiple and somewhat contradictory effects, CEACAM1 seems to influence melanoma invasion, migration, immunomodulation and tumour suppression, serving as a useful diagnostic biomarker and target for therapy. While the incidence of malignant melanoma has been increasing over the last decades without signs of prognosis improvement, it is crucial that new biomarkers for diagnosis and detection of metastatic progression are discovered, and CEACAM1 might be a viable option.

DOI: https://doi.org/10.2478/amtsb-2021-0069 | Journal eISSN: 2285-7079 | Journal ISSN: 2285-7079
Language: English
Page range: 37 - 39
Submitted on: Jul 13, 2021
Accepted on: Nov 26, 2021
Published on: Jan 24, 2022
Published by: Lucian Blaga University of Sibiu
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2022 Alexandra Chera, Alice Brînzea, published by Lucian Blaga University of Sibiu
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.